Compare Stocks

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CIDM Cinedigm	$1.17 -5.6%	$1.39	$0.27 ▼ $0.79	$218.69M	2.05	710,288 shs	110,966 shs
HHS Harte Hanks	$7.05 +1.7%	$2.70	$1.10 ▼ $3.96	$51.04M	0.64	14,914 shs	12,157 shs
PBSV Pharma-Bio Serv	$0.80 +6.7%	$0.88	$0.65 ▼ $1.10	$17.22M	0.51	1,415 shs	7,000 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CIDM Cinedigm	0.00%	-8.52%	-1.98%	-9.85%	+123,499,900.00%
HHS Harte Hanks	+1.73%	-2.89%	-8.56%	-7.84%	-19.24%
PBSV Pharma-Bio Serv	+6.67%	-6.76%	+0.76%	-23.81%	-20.00%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CIDM Cinedigm	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HHS Harte Hanks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBSV Pharma-Bio Serv	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CIDM Cinedigm	N/A	N/A	N/A	N/A
HHS Harte Hanks	N/A	N/A	N/A	N/A
PBSV Pharma-Bio Serv	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CIDM Cinedigm	$72.33M	3.02	N/A	N/A	N/A	∞
HHS Harte Hanks	$191.49M	0.27	$1.01 per share	6.99	$2.75 per share	2.56
PBSV Pharma-Bio Serv	$16.98M	1.08	$0.07 per share	11.46	$0.70 per share	1.14

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CIDM Cinedigm	N/A	-$0.05	N/A	∞	N/A	N/A	N/A	N/A	N/A
HHS Harte Hanks	-$1.57M	-$0.22	N/A	6.71	1.14	-0.82%	14.27%	2.52%	5/7/2024 (Estimated)
PBSV Pharma-Bio Serv	$1.31M	$0.03	26.68	7.27	N/A	4.05%	3.95%	3.10%	6/12/2024 (Estimated)

Latest HHS, PBSV, and CIDM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2024	Q1 2024	PBSV Pharma-Bio Serv	$0.02	-$0.01	-$0.03	-$0.01	$5.00 million	$2.38 million
3/14/2024	Q4 2023	HHS Harte Hanks	N/A	$0.35	+$0.35	$0.97	$47.00 million	$49.49 million
1/29/2024	Q4 2023	PBSV Pharma-Bio Serv	$0.03	$0.03	N/A	N/A	$5.00 million	$3.60 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CIDM Cinedigm	N/A	N/A	N/A	N/A	N/A
HHS Harte Hanks	N/A	N/A	N/A	N/A	N/A
PBSV Pharma-Bio Serv	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CIDM Cinedigm	N/A	N/A	N/A
HHS Harte Hanks	N/A	1.36	1.36
PBSV Pharma-Bio Serv	N/A	5.10	5.10

Ownership

Institutional Ownership

Company	Institutional Ownership
CIDM Cinedigm	8.03%
HHS Harte Hanks	33.75%
PBSV Pharma-Bio Serv	N/A

Insider Ownership

Company	Insider Ownership
CIDM Cinedigm	16.40%
HHS Harte Hanks	12.28%
PBSV Pharma-Bio Serv	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CIDM Cinedigm	140	186.92 million	N/A	Not Optionable
HHS Harte Hanks	1,962	7.24 million	6.35 million	Not Optionable
PBSV Pharma-Bio Serv	100	22.96 million	20.21 million	Not Optionable

HHS, PBSV, and CIDM Headlines

Source	Headline
	Pharma-Bio Serv (OTCMKTS:PBSV) Shares Cross Below Two Hundred Day Moving Average of $0.92 americanbankingnews.com - April 18 at 3:44 AM
	Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations markets.businessinsider.com - April 16 at 3:38 AM
	Pharma-Bio Serv (OTCMKTS:PBSV) Stock Crosses Above 50 Day Moving Average of $0.89 americanbankingnews.com - April 10 at 4:32 AM
	Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment Program tmcnet.com - April 9 at 8:56 AM
	Looking Into Biomarin Pharmaceutical's Recent Short Interest benzinga.com - April 3 at 3:20 PM
	PBSV Releases Quarterly Results finance.yahoo.com - March 19 at 3:02 PM
	Pharma-Bio Serv reports Q1 results seekingalpha.com - March 19 at 10:01 AM
	Pharma-Bio Serv Announces Results for the Quarter… pharmiweb.com - March 19 at 12:00 AM
	Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024 accesswire.com - March 18 at 5:10 PM
	Buy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial Outlook markets.businessinsider.com - March 4 at 11:00 PM
	Maintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market Uncertainties markets.businessinsider.com - March 4 at 12:58 PM
	BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update marketwatch.com - February 26 at 4:21 PM
	Strong Voxzogo Performance Underpins Buy Rating for BioMarin Pharmaceutical markets.businessinsider.com - February 23 at 8:53 PM
	Pharma-Bio Serv reports revenue of $17M for 2023 newsismybusiness.com - January 31 at 7:39 AM
	Regeneron Acquires 2seventy Bio Platforms and Preclinical & Clinical Programs contractpharma.com - January 30 at 4:38 PM
	PBSV Expands Margins and Markets finance.yahoo.com - January 30 at 4:38 PM
	Jubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger Deal msn.com - January 28 at 10:10 AM
	BridgeBio Pharma inks $1.25bn pehub.com - January 23 at 12:11 PM
	Optimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth Drivers markets.businessinsider.com - January 9 at 8:52 PM
	BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner seekingalpha.com - January 8 at 8:02 AM
	PBSV Reward Shareholders with High Yield finance.yahoo.com - January 3 at 3:22 PM
	Pharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special Dividend finanznachrichten.de - December 21 at 1:54 PM
	AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? msn.com - December 8 at 8:18 AM
	BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany markets.businessinsider.com - November 28 at 9:18 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cinedigm

NASDAQ:CIDM

Cineverse Corp. is a global streaming technology and entertainment company. It owns and operates streaming channels, all powered by its advanced, proprietary technology platform. The firm currently features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. It entertains consumers around the globe by providing premium feature films and television series, enthusiast streaming channels, and technology services to some media, retail, and technology companies. The company was founded by A. Dale Mayo on March 31, 2000 and is headquartered in New York, NY.

Harte Hanks

NYSE:HHS

Harte-Hanks, Inc. engages in the provision of marketing solutions. It specializes in consulting, data analytics, creative services, digital and social media, marketing strategy, marketing technology, and other related services. It supports a range of customers in the field of technology, travel and leisure, entertainment, pharmaceuticals, automotive, finance, and retail. The company was founded in 1923 and is headquartered in San Antonio, TX.

Pharma-Bio Serv

OTCMKTS:PBSV

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial